Photofrin

Company
QLT

Approval Status
Approved January 1998

Treatment for
Non-small cell lung cancer

Areas
Cancer & Oncology

QLT PhotoTherapeutics' light-activated drug Photofrin (porfimer sodium) was approved for injection in treating early-stage, microinvasive lung cancer. It is approved for use in patients with microinvasive endobronchial non-small cell lung cancer at an early stage, for whom surgery and radiotherapy are not indicated.

Photofrin Drug Information

The Photofrin drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top